Clinical Trial Update: An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease [Phase 3]

View source ↗

Summary

An open-label extension study evaluated the long-term efficacy and safety of the rivastigmine transdermal patch in patients with probable Alzheimer's disease. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Rivastigmine Transdermal Patch (rivastigmine)

Snippet

Sponsor: Novartis | Conditions: Alzheimer's Disease | Phase 3 | Status: COMPLETED